Therapeutic efficacy and effects of artesunate-mefloquine and mefloquine alone on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria.
The treatment efficacy and effects of artesunate-mefloquine (AMQ) and mefloquine (MQ) on malaria-associated anemia (MAA) were evaluated in 342 children <or= 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug/drug combination. All children recovered clinically. Fever clearance times were similar. Parasite clearance was significantly faster with AMQ (mean +/- SD = 1.4 +/- 0.6 days, 95% confidence interval [CI] = 1.3-1.5, P < 0.0001), but polymerase chain reaction-corrected cure rates were similar (97% versus 94%). Gametocyte carriage rates and the drug-attributable fall in hematocrit were significantly lower with AMQ (mean +/- SD = 4.8 +/- 3.8%, 95% CI = 3.6-6.0, P = 0.03), but the rates of resolution of MAA were similar. Both regimens were well tolerated. AMQ clears parasitemia and reduces gametocyte carriage more rapidly and causes lesser fall in hematocrit than MQ, but both regimens are effective treatment of uncomplicated P. falciparum malaria in Nigerian children.